International Agency for Research on Cancer (IARC) - Summaries & Evaluations


VOL.: 9 (1975) (p. 135)

5. Summary of Data Reported and Evaluation

5.1 Animal carcinogenicity data

Cyclophosphamide is carcinogenic in mice and rats following its intraperitoneal injection, in rats following its intravenous injection and in mice following its subcutaneous injection, in doses similar to those used in clinical practice. It produced mainly lung and lymphoreticular tumours, and also tumours of the liver and reproductive organs, sarcomas and squamous-cell carcinomas of the skin.

5.2 Human carcinogenicity data

The available case reports in which tumours were reported to have occurred in patients treated with cyclophosphamide provide insufficient evidence to determine if there is an increased risk of cancer following the therapeutic use of this drug, with the possible exception of cancer of the bladder.

Subsequent evaluations: Vol. 26 (1981); Suppl. 7 (1987)

Last updated: 21 March 1998

    See Also:
       Toxicological Abbreviations
       Cyclophosphamide (ICSC)
       Cyclophosphamide  (IARC Summary & Evaluation, Supplement7, 1987)
       Cyclophosphamide (IARC Summary & Evaluation, Volume 26, 1981)